Abstract
The aim of subcellular pharmacokinetics in drug design is to model drug disposition and response as a function of the properties of drugs and biosystems involved and the observation time. Biosystems are represented by systems of alternating membranes and aqueous phases that differ in acidity and contain low-molecular cell constituents, enzymes and other proteins. The resulting disposition models are combined with linear free-energy assumptions, drug/receptor binding kinetics and relationships between receptor binding and response to produce model-based quantitativestructure–(time–)activity relationships, QS(T)AR. This review summarizes the present status of subcellular pharmacokinetics with emphasis on passive trans-bilayer transport. In particular, mechanisms of transport are analyzed with respect to amphiphilicity and lipophilicity. The overall rate of transport is strongly governed by amphiphilicity, the tendency of drug molecules to adsorb to the bilayer/water interface. Depending on amphiphilicity, the time needed for a drug to cross a single bilayer ranges from seconds to days. The main advantage of the subcellular pharmacokinetic approach is that the resulting models, once calibrated for a given biosystem, provide a detailed recipe for tailoring the drug properties to ensure optimum disposition.
Similar content being viewed by others
References
Prentis, R.A., Lis, Y. and Walker, S.R., Br. J. Clin. Pharmacol., 25 (1988) 387.
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J., Adv. Drug Deliv. Rev., 23 (1997) 3.
Kansy, M., Senner, F. and Gubernator, K., J. Med. Chem., 41 (1998) 1007.
Ajay, A., Walters, W.P. and Murcko, M.A., J. Med. Chem., 41 (1998) 3314.
Rowland, M. and Tozer, T.N., Clinical Pharmacokinetics. Concepts and Applications, 3rd ed., Williams & Wilkins, Media, PA, 1995.
Blakey, G.E., Nestorov, I.A., Arundel, P.A., Aarons, L.J. and Rowland, M., J. Pharmacokinet. Biopharm., 25 (1997) 277.
Chou, C.H., Aarons, L. and Rowland, M., J. Pharmacokinet. Biopharm., 26 (1998) 595.
Penniston, J.T., Beckett, L., Bentley, D.L. and Hansch, C., Mol. Pharmacol., 5 (1969) 333.
Ueda, K., Taguchi, Y. and Morishima, M., Semin. Cancer Biol., 8 (1997) 151.
Leo, A. and Weininger, D., Biobyte Corp., Claremont, CA, 1995.
Yoshino, A., Yoshida, T., Okabayashi, H., Kamaya, H. and Ueda, I., J. Colloid Interface Sci., 198 (1998) 319.
Hansch, C. and Fujita, T., J. Am. Chem. Soc., 86 (1964) 1616.
Moring, J., Niego, L.A., Ganley, L.M., Trumbore, M.W. and Herbette, L.G., Biophys. J., 67 (1994) 2376.
Eisenberg, D., Weiss, R.M. and Terwilliger, T.C., Nature, 299 (1982) 371.
Brasseur, R., Vandenbosch, C., Van den Bossche, H. and Ruysschaert, J.M., Biochem. Pharmacol., 32 (1983) 2175.
Balaz, S., Wiese, M. and Seydel, J.K., J. Pharm. Sci., 81 (1992) 849.
Kamp, F. and Hamilton, J.A., Proc. Natl. Acad. Sci. USA, 89 (1992) 11367.
Classen, J., Deuticke, B. and Haest, C.W., J. Membr. Biol., 111 (1989) 169.
Chowhan, Z.T., Yotsuyanagi, T. and Higuchi, W.I., Biochim. Biophys. Acta, 266 (1972) 320.
Serra, M.V., Kamp, D. and Haest, C.W., Biochim. Biophys. Acta, 1282 (1996) 263.
Kedem, O. and Katchalsky, A., Biochim. Biophys. Acta, 27 (1958) 229.
Subczynski, W.K., Hyde, J.S. and Kusumi, A., Proc. Natl. Acad. Sci. USA, 86 (1989) 4474.
Cabrini, G. and Verkman, A.S., Biochim. Biophys. Acta, 862 (1986) 285.
Marx, U., Lassmann, G., Wimalasena, K., Muller, P. and Herrmann, A., Biophys. J., 73 (1997) 1645.
Kuzelova, K. and Brault, D., Biochemistry, 33 (1994) 9447.
Regev, R. and Eytan, G.D., Biochem. Pharmacol., 54 (1997) 1151.
Pebay, P.E., Dufourc, E.J. and Szabo, A.G., Biophys. Chem., 53 (1994) 45.
Wenk, M.R., Alt, T., Seelig, A. and Seelig, J., Biophys. J., 72 (1997) 1719.
Marrink, S.J., Jahnig, F. and Berendsen, H.J., Biophys. J., 71 (1996) 632.
Wilson, M.A. and Pohorille, A., J. Am. Chem. Soc., 118 (1996) 6580.
Marrink, S.J. and Berendsen, H.J.C., J. Phys. Chem., 100 (1996) 16729.
Bassolino, D., Alper, H. and Stouch, T.R., Drug Des. Discov., 13 (1996) 135.
Pidgeon, C., Ong, S.W., Liu, H.L., Qiu, X.X., Pidgeon, M., Dantzig, A.H., Munroe, J., Hornback, W.J., Kasher, J.S., Glunz, L. and Sczerba, T., J. Med. Chem., 38 (1995) 590.
Yang, C.Y., Cai, S.J., Liu, H.L. and Pidgeon, C., Adv. Drug Deliv. Rev., 23 (1997) 229.
Van de Waterbeemd, H. and Kansy, M., Chimia, 46 (1992) 299.
Chikhale, E.G., Ng, K.Y., Burton, P.S. and Borchardt, R.T., Pharm. Res., 11 (1994) 412.
Leahy, D.E., Taylor, P.J. and Wait, A.R., Quant. Struct.—Act. Relat., 8 (1989) 17.
Xiang, T.X. and Anderson, B.D., J. Membr. Biol., 140 (1994) 111.
Balaz, S. and Sturdik, E., In Tichy, M. (Ed.) QSAR in Toxicology and Xenobiochemistry, Elsevier, Amsterdam, 1985, pp. 257–267.
Kubinyi, H., J. Pharm. Sci., 67 (1978) 262.
Van de Waterbeemd, H., van Bakel, H. and Jansen, A., J. Pharm. Sci., 70 (1981) 1081.
Kubinyi, H., J. Med. Chem., 20 (1977) 625.
Balaz, S., Sturdik, E., Hrmova, M., Breza, M. and Liptaj, T., Eur. J. Med. Chem., 19 (1984) 167.
Dearden, J.C., Environ. Health Perspect., 61 (1985) 203.
Flynn, G.L. and Yalkowsky, S.H., J. Pharm. Sci., 61 (1972) 838.
Balaz, S., Sturdik, E., Dibus, I., Ebringer, L., Stibranyi, L. and Rosenberg, M., Chem.-Biol. Interact., 55 (1985) 93.
Collander, R., Acta Chem. Scand., 5 (1951) 774.
Balaz, S., Quant. Struct.—Act. Relat., 13 (1994) 381.
Balaz, S. and Sturdik, E., Gen. Physiol. Biophys., 4 (1985) 105.
Dvorsky, R., Balaz, S. and Sawchuk, R.J., J. Theor. Biol., 185 (1997) 213.
Balaz, S., Sturdik, E. and Augustin, J., Biophys. Chem., 24 (1986) 135.
Balaz, S., SAR QSAR Environ. Sci., 4 (1995) 177.
Balaz, S., Sturdik, E. and Augustin, J., Bull. Math. Biol., 50 (1988) 367.
Higuchi, T. and Davis, S.S., J. Pharm. Sci., 59 (1970) 1376.
Hyde, R.M., J. Med. Chem., 18 (1975) 231.
Martin, Y.C. and Hackbarth, J.J., J. Med. Chem., 19 (1976) 1033.
Martin, Y.C., In Franke, R. and Oehme, P. (Eds.) Quantitative Structure—Activity Analysis, Akademie-Verlag, Berlin, 1978, pp. 351–358.
Martin, Y.C., Quantitative Drug Design. A Critical Introduction, Marcel Dekker, New York, NY, 1978.
Martin, Y.C., In Yalkowsky, S.H., Sinkula, A.A. and Valvani, S.C. (Eds.) Physical Chemical Properties of Drugs, Marcel Dekker, New York, NY, 1980, pp. 49–110.
Martin, Y.C., In Martin, Y.C., Kutter, E. and Austel, V. (Eds.) Modern Drug Research. Paths to Better and Safer Drugs, Marcel Dekker, New York, NY, 1989, pp. 161–216.
Pirselova, K. and Balaz, S., Chemometr. Intell. Lab. Syst., 24 (1994) 193.
Balaz, S., Sturdik, E. and Tichy, M., Quant. Struct.—Act. Relat., 4 (1985) 77.
Balaz, S., Wiese, M., Chi, H.L. and Seydel, J.K., Anal. Chim. Acta, 235 (1990) 195.
Watanabe, J. and Kozaki, A., Chem. Pharm. Bull., 26 (1978) 665.
Balaz, S., Pirselova, K., Schultz, T.W. and Hermens, J., J. Theor. Biol., 178 (1996) 7.
Pirselova, K., Balaz, S. and Schultz, T.W., Arch. Environ. Contam. Toxicol., 30 (1996) 170.
Balaz, S., Cronin, M.T.D. and Dearden, J.C., Pharm. Sci. Commun., 4 (1993) 51.
Pirselova, K., Balaz, S., Sturdik, E., Ujhelyova, R., Veverka, M., Uher, M. and Brtko, J., Quant. Struct.—Act. Relat., 16 (1997) 283.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baláž, Š. Lipophilicity in trans-bilayer transport and subcellular pharmacokinetics. Perspectives in Drug Discovery and Design 19, 157–177 (2000). https://doi.org/10.1023/A:1008775707749
Issue Date:
DOI: https://doi.org/10.1023/A:1008775707749